Evidence map›Paper›PMID 40693204›Full record

ReviewFrontiers in nutrition2025

Clinical evidence and mechanistic pathways of human milk oligosaccharide supplementation for health benefits: an updated review.

Tanjina Amin, Md Mahmudul Amin, Adikari Arachchige Dilki Indrachapa Adikari, Xiaoming Zheng, Yibing Ning, Bing Wang

Abstract readReview
In one paragraph

Review in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. A Synbiotic of Lacto-Nutrients · 2026
    Article
  4. Article
  5. Metabolic interactions and growth dynamics ofFrontiers in microbiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tanjina AminGulbali Institute, School of Agricultural, Environmental, and Veterinary Sciences, Charles Sturt University, Wagga Wagga, NSW, Australia.
Md Mahmudul AminGulbali Institute, School of Agricultural, Environmental, and Veterinary Sciences, Charles Sturt University, Wagga Wagga, NSW, Australia.
Adikari Arachchige Dilki Indrachapa AdikariGulbali Institute, School of Agricultural, Environmental, and Veterinary Sciences, Charles Sturt University, Wagga Wagga, NSW, Australia.
Xiaoming ZhengGulbali Institute, School of Agricultural, Environmental, and Veterinary Sciences, Charles Sturt University, Wagga Wagga, NSW, Australia.
Yibing NingNutrition Research Institute, Junlebao Dairy Group Co., Ltd, Shijiazhuang, China.
Bing WangGulbali Institute, School of Agricultural, Environmental, and Veterinary Sciences, Charles Sturt University, Wagga Wagga, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human milk oligosaccharides (HMOs), a diverse group of complex sugars, are increasingly recognized for their health advantages for infants. These bioactive molecules are believed to be critical in shaping gut microbiota, infant immunity, and overall health. Recent clinical studies have focused on supplementation of infant formulas with manufactured HMOs to replicate some of the benefits observed in breastfed infants. This review aims to summarize the latest evidence from human clinical trials on manufactured HMO supplementation, highlighting its associated health benefits and the underlying mechanisms of action. A comprehensive literature search was conducted using PubMed, Medline, and Scopus databases from 1964 to 2024, identifying clinical intervention studies on manufactured HMOs across different populations, ranging from pre-term infants to adults with or without medical conditions. Findings reveal that manufactured HMOs are safe, well-tolerated, and show promising benefits for immune health and gut microbiota composition, closely mirroring the effects of natural HMOs found in breast milk. Although studies have explored the prebiotic role of HMOs in modulating neuroactive metabolites such as short-chain fatty acids (SCFAs) produced by gut microbiota, there is a notable lack of research directly evaluating the cognitive outcomes of HMOs using MRI or standardized developmental assessment tools. Furthermore, this review highlights two novel clinical findings: the potential therapeutic role of HMOs in obesity prevention by promoting fat loss while preserving muscle mass and their beneficial effects in osteoarthritis by reducing pain and enhancing mobility. However, the variability in dosage, participant groups, intervention duration, and outcomes, along with the limited studies on the mechanistic pathways of HMOs, makes it difficult to draw definitive conclusions, underscoring the need for well-designed clinical trials across diverse health conditions to better understand the full potential of HMO supplementation.

Indexed as

gut-microbiotahuman milk oligosaccharidesinfant formulainfectionmechanistic pathway

Identifiers

PMID40693204
PMCPMC12278615

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.